Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Organometallic gold(III) complexes with hybrid SNS-donating thiosemicarbazone ligands: cytotoxicity and anti-Trypanosoma cruzi activity

Full text
Maia, P. I. da S. ; Carneiro, Z. A. ; Lopes, C. D. ; Oliveira, C. G. ; Silva, J. S. ; de Albuquerque, S. ; Hagenbach, A. ; Gust, R. ; Deflon, V. M. ; Abram, U.
Total Authors: 10
Document type: Journal article
Source: DALTON TRANSACTIONS; v. 46, n. 8, p. 2559-2571, 2017.
Web of Science Citations: 15

Stable organogold(III) compounds of the composition {[}Au-III(Hdamp)(L1)]Cl are formed from reactions of {[}AuCl2(damp)] with H(2)L1 (damp(-) = dimethylaminomethylphenyl; H(2)L1 = N'-(diethylcarbamothioyl)benz-imidothiosemicarbazides). The cationic complexes can be neutralized by reactions with weak bases under the formation of {[}Au-III(damp)(L1)] compounds. The structures of the products show interesting features like relatively short Au center dot center dot center dot H contacts between the methylene protons of the Hdamp ligand and the gold(III) ions. Preliminary biological studies on the uncoordinated compounds H(2)L1 and their gold complexes indicate considerable cytotoxicity for the {[}Au-III(Hdamp)(L1)]Cl complexes against MCF-7 cells. The in vitro trypanocidal activity was evaluated against the intracellular form of Trypanosoma cruzi. The organometallic complexes display a remarkable activity, which is dependent on the alkyl substituents of the thiosemicarbazone building blocks of the ligands. One representative of the cationic {[}Au-III(Hdamp)(L1)]Cl complexes, where H(2)L1 contains a dimethylthiosemicarbazide building block, shows a trypanocidal activity against the intracellular amastigote form in the same order of magnitude as that of the standard drug benznidazole. Furthermore, no appreciable toxicity to mice spleen cells is observed for this compound resulting in a therapeutic index of about 30, which strongly recommends it as a promising candidate for the development of a future antiparasitic drug. (AU)

FAPESP's process: 11/16380-1 - Au, Re and Tc thiosemicarbazones complexes of interest in the development pharmaceuticals or radiopharmaceuticals for diagnostic or therapy
Grantee:Pedro Ivo da Silva Maia
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 09/54011-8 - Acquisition of a single-crystal X-ray diffractometer for the structural analysis of small molecules and proteins
Grantee:Victor Marcelo Deflon
Support Opportunities: Multi-user Equipment Program